Fig. 3From: Development of a novel prognostic score combining clinicopathologic variables, gene expression, and mutation profiles for lung adenocarcinomaRFS analysis results. a Sketch of disease process for patients after initial treatment. b Estimated cumulative probabilities for recurrence and estimated survival (1, cumulative probability) for death without recurrence, using either competing risks modeling (Cpr) or naïve KM modeling (KM). c The cumulative probability of developing recurrence and death without recurrence. d Comparison of time-dependent AUCs of risk scores for RFS predictionBack to article page